Evonetix Ltd.

DUBLIN--( BUSINESS WIRE )--The "Global Enzymatic DNA Synthesis Market: Analysis By Product Type (DNA Library Synthesis and Custom DNA Synthesis), By Technology, By Application, By End User, By Region, Size, Trends and Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. The latest industry analysis on the global enzymatic DNA synthesis market projects a robust growth trend as the sector witnesses high demand fueled by breakthroughs in synthetic biology, genetic engineering, and therapeutic applications. According to the report, the market, which stood at US$253.42 million in 2022, is forecasted to reach US$2.11 billion by 2028, expanding at an impressive compound annual growth rate (CAGR) of 42.43% during the period from 2023 to 2028. The research provides a detailed segmentation of the market, offering insightful data on various product types, technologies, applications, and end-users. Within the product type realm, the DNA Library Synthesis segment commands a significant share, underscoring its integral role in genomics and proteomics research, while the Custom DNA Synthesis sector also exhibits substantial growth potential. In terms of technology, Polymerase Chain Reaction (PCR) technology remains a cornerstone, supporting a multitude of applications, from DNA manipulation to molecular diagnostics. Meanwhile, emerging technologies such as CRISPR and cell-free synthetic biology are identified as disruptive trends shaping the market considerably. The application of enzymatic DNA synthesis in synthetic biology dominates the market, propelled by innovative developments in the fabrication of synthetic genes and organisms. The report elucidates that therapeutic antibodies, genetic engineering, and vaccine design are pivotal applications driving demand in this innovative market. Regional Insights Geographically, North America leads the market, showcasing a robust infrastructure and extensive research initiatives. Yet, it is the Asia Pacific region that is forecasted to emerge as the fastest-growing market in the coming years, attributed to increased investments in genomic research, personalized medicine, and burgeoning scientific endeavors across academic and research institutions in the region. Market Dynamics and Future Growth Engines Rising prevalence of genetic disorders – As the understanding of genetic diseases expands, demand escalates for novel DNA-based diagnostic and therapeutic strategies. Technological advancements – With continuous enhancements in enzymes and synthetic methods, enzymatic DNA synthesis is increasingly capable of delivering high precision and customization. Synthetic biology applications – Adoption of enzymatic synthesis in crafting biological systems fuels the growth of this scientific field, offering potent growth prospects for the market. CRISPR-Cas9 integration – The incorporation of CRISPR-Cas9 in enzymatic DNA synthesis heralds a new era of precision in genetic manipulation, augmenting market expansion. While the industry navigates challenges such as stringent regulations and complex operational procedures, the continuous innovation and the integration of CRISPR-Cas9 make it primed for overcoming these hurdles effectively. Competitive Landscape and Key Industry Disruptors The competitive landscape of the enzymatic DNA synthesis market is characterized by a blend of established players and emerging startups, each contributing novel solutions that redefine DNA synthesis capabilities. This competition is intensified by ongoing efforts in research and development, aimed at creating more sophisticated and efficient enzymes. Key Players Profiled: Telesis Bio Inc. Twist Bioscience Corporation GenScript Biotech Corp. Evonetix Ansa Biotechnologies, Inc. Camena Bio Molecular Assemblies DNA Script Touchlight Kern Systems These industry dynamics reveal a progressive market trajectory, with enzymatic DNA synthesis cementing itself as a cornerstone technology in the biotech landscape and a critical catalyst for future scientific advancements. Key Attributes: Report Attribute Details No. of Pages 157 Forecast Period 2022 - 2028 Estimated Market Value (USD) in 2022 $0.25 Billion Forecasted Market Value (USD) by 2028 $2.11 Billion Compound Annual Growth Rate 42.4% Regions Covered Global For more information about this report visit https://www.researchandmarkets.com/r/dvq8rd About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

The companies are working together on next-generation technology in the fast-growing field of synthetic biology. This new technology will improve the quality, speed, and cost of developing synthetic biological solutions such as life-saving vaccines, medicines, treatments, and therapies. CAMBRIDGE, England--(BUSINESS WIRE)-- EVONETIX LTD (‘Evonetix’), the company developing semiconductor scale technology to improve access to gene synthesis, today announces the signing of a joint development agreement and commercial supply agreement with Analog Devices, Inc. (ADI), a global semiconductor leader. This agreement signals the continuation of the long-standing combined work of both companies, bringing efforts to the next stage in producing a new technology benchmark that will help meet the global demand for better gene synthesis. Current gene synthesis approaches can be slow, expensive, and inaccurate, potentially causing a huge bottleneck for innovation. Centralized DNA production services struggle to deliver length, accuracy, and complexity at speed. Evonetix has reimagined gene synthesis and is developing a completely new approach that will release the potential of novel biologic therapies and drive advances in engineering biology faster and further. Together with ADI, Evonetix is developing a gene foundry on a chip, which will consign the service model to history. Evonetix envisages preparing gene length DNA in three days at the benchtop, accelerating the design-build-test cycle for antibodies, vaccines, and proteins from months to days, and delivering as much as a 10-fold productivity increase in gene delivery. Today’s agreement underlines the work in taking the development of ADI’s application specific integrated circuit (ASIC), which is designed to thermally control DNA synthesis and assembly to the next level by providing a turn-key semiconductor solution for Evonetix’s Evaleo® series of DNA synthesis devices. In the latest agreements between the companies, ADI has committed to investing in the continued development of the Evonetix semiconductor-based gene synthesis family of devices. The companies have also entered into a commercial supply agreement to secure the highly scalable manufacturing capability of ADI for Evonetix and its future customers. Matthew Hayes, Founder and CTO at Evonetix, said: “This agreement with global semiconductor leader ADI represents a major milestone for Evonetix and is a strong validation of our vision and our technology. This provides us with the capacity and manufacturing capabilities required as we continue our efforts to bring our technology closer to market, putting the power of gene synthesis directly in the hands of researchers.” Patrick O’Doherty, Senior Vice President of Digital Healthcare at ADI, added: “ADI’s efforts with Evonetix will be central to the manufacturing and commercialization of their benchtop gene synthesis platform. We see the interface between silicon and biology as critical for the future development of therapeutics to help treat disease, and we are delighted to work with Evonetix on this.” View source version on businesswire.com: Contacts Zyme Communications Francesca Wallace Email: francesca.wallace@zymecommunications.com Source: Evonetix View this news release online at:

External placement marks a key milestone in the development of Evonetix’s benchtop DNA synthesis technology, in preparation for customer use and commercialization CAMBRIDGE, England--(BUSINESS WIRE)-- EVONETIX LTD (‘Evonetix’), the Company developing semiconductor scale technology to improve access to gene synthesis, today announced its first placement of a DNA synthesis development platform for evaluation at Imperial College London. This is the Company’s first platform to be installed in an external scientific setting; a significant milestone as it continues to optimize its gene synthesis technology in preparation for customer use and commercialization. The platform has been placed in labs led by Dr Marko Storch, Head of Synthetic Biology and Automation, London Biofoundry, and Professor Paul Freemont, Head of Structural and Synthetic Biology, Department of Infectious Disease, Imperial College London. The installation of this platform follows the delivery of Evonetix’s chip-synthesized DNA for evaluation to Dr Jenny Molloy, Co-chair of the Engineering Biology Interdisciplinary Research Centre at the University of Cambridge earlier this year.1 Evonetix’s DNA synthesis platform combines patented semiconductor chip design and proprietary, thermally controlled synthesis chemistry, bringing novel approaches to chemistry and process control to enable DNA synthesis on the benchtop of any lab. Better access to gene-length DNA will be transformative for engineering biology research, with applications across the healthcare, biotech, agriculture, and food industries. Colin McCracken, Chief Executive Officer at Evonetix, said: “Reaching this major milestone demonstrates continued confidence in the progress of our technology and represents a significant step forward in delivering on our vision to place benchtop gene synthesis into the hands of all researchers.” Dr Marko Storch, Head of Synthetic Biology and Automation, London Biofoundry, Imperial College London, commented: “Evonetix’s platform is an exciting new development in DNA synthesis, and we are delighted to have the opportunity to host it in our lab. Rapid access to gene-length DNA synthesis will transform our research capabilities and drive the development of our sophisticated and innovative automation platforms and workflows to support cutting-edge synthetic biology research.” Dr Paul Freemont, Head of Structural and Synthetic Biology, Department of Infectious Disease, Imperial College London, added: “We are excited to be the first to receive Evonetix’s DNA synthesis platform. The limitations of the current service model for accessing long synthetic DNA, including turnaround time and costs, create barriers in our synthetic biology research. Evonetix’s technology has the potential to completely change the way we produce and use DNA, enabling flexibility and speed that will have a significant impact on the way we conduct our research into human disease and infection.” 1. Press release (10th May, 2023) Evonetix delivers first chip-synthesized DNA to the University of Cambridge View source version on businesswire.com: Contacts Francesca Wallace Zyme Communications Tel: +44(0)7506424870 Email: francesca.wallace@zymecommunications.com Source: Evonetix View this news release online at: